OSE ImmunotherapeuticsORPOF 41 Pretax Margin % is -1,730.57% as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.36 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 946 Biotechnology companies, OSE Immunotherapeutics ranks worse than 81.71% on this metric.
The historical rank and industry rank for OSE Immunotherapeutics's Pretax Margin % or its related term are showing as below:
ORPOF'
s Pretax Margin % Range Over the Past 10 Years
Min: -1428.56 Med: -81.95 Max: 4593.21
Current: -1428.56
ORPOF's Pretax Margin % is ranked worse than 81.71% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs ORPOF: -1428.56
OSE Immunotherapeutics (OTCPK:ORPOF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
OSE Immunotherapeutics Pretax Margin % Related Terms
OSE Immunotherapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for OSE Immunotherapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORPOF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, OSE Immunotherapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSE Immunotherapeutics (ORPOF) has a Pretax Margin % of -1,730.57% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #773 out of 946 companies in the Biotechnology industry, placing it in the top 81.7%.
Is OSE Immunotherapeutics' Pretax Margin % too high?
OSE Immunotherapeutics' current Pretax Margin % is -1,730.57%. Based on the distribution chart, OSE Immunotherapeutics ranks #773 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #773 out of 946 companies for Pretax Margin %. This places OSE Immunotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Pretax Margin % is -1,730.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.43 — trading 31.8% above its estimated fair value. The current Pretax Margin % is -1,730.57%. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Pretax Margin % is -1,730.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 31.8% above its estimated GF Value™ of $3.36.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
Pretax Margin %: -1,730.57%
GF Value™: $3.36 vs. price of $4.43 (31.8% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score
Get the complete analysis for ORPOF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
